Sangamo Therapeutics (NASDAQ:SGMO) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, risk, earnings, analyst recommendations and profitability.
Valuation & Earnings
This table compares Sangamo Therapeutics and Cellectis’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sangamo Therapeutics||$84.45 million||11.60||-$68.33 million||($0.70)||-12.10|
|Cellectis||$21.43 million||20.56||-$78.69 million||($1.93)||-5.38|
Sangamo Therapeutics has higher revenue and earnings than Cellectis. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of current ratings and recommmendations for Sangamo Therapeutics and Cellectis, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Sangamo Therapeutics currently has a consensus price target of $14.00, suggesting a potential upside of 65.29%. Cellectis has a consensus price target of $34.60, suggesting a potential upside of 233.33%. Given Cellectis’ stronger consensus rating and higher probable upside, analysts clearly believe Cellectis is more favorable than Sangamo Therapeutics.
Institutional and Insider Ownership
69.0% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 31.7% of Cellectis shares are owned by institutional investors. 1.3% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
This table compares Sangamo Therapeutics and Cellectis’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Sangamo Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Cellectis has a beta of 1.74, suggesting that its stock price is 74% more volatile than the S&P 500.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Cellectis Company Profile
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.